How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | UTHRUNITED THERAPEUTICS Corp | NTRANatera, Inc. | 950200.KQ950200.KQ | RVMDRevolution Medicines, Inc. | Median of the restexcluding UTHR |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $563.49▲ 9.61 (1.74%) | $401.37▼ 12.01 (2.91%) | ₩2965.00▲ 35.00 (1.19%) | $194.28▼ 2.27 (1.15%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 8.7/10 | 4.7/10 | 4.7/10 | 2.0/10 | 4.7/10 |
| Market value | $24.59B | $56.07B | $57.03B | $38.27B | |
| Revenue | $3.18B | $2.31B | $59.19B | $0.00 | |
| Profit | $1.33B | -$208.2M | -$2.98B | -$1.13B | |
| Revenue growthChange in sales versus the prior year. | 10.6% | 35.9% | 35.6% | — | 35.7% |
| Gross marginShare of sales left after the direct cost of producing them. | 87.9% | — | 24.5% | — | 24.5% |
| Operating marginShare of sales left after running the business, before interest and tax. | 46.9% | -13.4% | -3.8% | — | -8.6% |
| Profit marginProfit kept from each dollar of sales. | 41.9% | -9.0% | -5.0% | — | -7.0% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 32.7% | 4.7% | -0.1% | — | 2.3% |
| Return on equityProfit against the owners' stake in the company. | 18.8% | -12.2% | -10.9% | -69.3% | -12.2% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 21.0% | -34.2% | -8.2% | -74.9% | -34.2% |
| P/E ratioPrice paid per dollar of annual profit. | 18.43x | — | — | — | — |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | — | 17.56x | — | 17.56x |
| Price to book | 3.47x | 32.74x | 2.09x | 23.46x | 23.46x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.11x | 0.40x | 0.88x | 0.44x | 0.44x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 7/8 | 2/7 | 7/8 | 1/7 | 2.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | distress | distress | safe |
How UTHR compares with the others
- UTHR's operating margin of 46.9% is higher than the median of the other companies selected (-8.6%).
- Its revenue grew more slowly than the median of the other companies selected: 10.6% against 35.7%.
- Its liabilities are lower relative to equity than the median of the other companies selected: 0.1x against 0.4x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.